A NEW DIRECTION FOR CNS DISCOVERY
The biology points forward.
The patient need guides us back.
We are developing Complementary Duality: an AI-enabled platform that connects scientific evidence with the requirements of a future therapy.
CANDIDATE ASSETS SigmaGate & Synapto
Built on experience.
Focused on what comes next.
01 / THE PLATFORM
Complementary Duality is being designed to ask two questions together: what does the evidence support, and what must be true for that idea to become a viable therapy?
FROM BIOLOGY TO POSSIBILITY
Start with targets, mechanisms, compounds, and combinations. Connect each claim to its evidence, assumptions, and competing explanations.
The output: a supported path and its unresolved links.
FROM PATIENT NEED TO REQUIREMENTS
Begin with the intended population, benefit, and regimen. Work backward through the exposure, safety, delivery, and evidence needed to support the claim.
The output: necessary conditions and discriminating tests.
FROM UNCERTAINTY TO ACTION
Reconcile both directions against shared criteria. Record contradictions, retain expert review, and decide whether to continue, hold, redirect, or stop the stated path.
The output: an auditable research decision packet.
i Agreement between the two directions identifies compatibility. Biological validity still requires experiments.
THE INVESTMENT THESIS
The proposed value is a reusable decision layer: a way to evaluate more development paths and make the reasoning behind each capital decision inspectable.
Evaluate combinations of mechanisms and indications within a shared framework, with each branch earning its next step.
Surface missing evidence and decisive constraints early enough to shape the next experiment and its funding decision.
Preserve evidence, alternatives, expert review, and decision history in a packet that a research team or partner can inspect.
Platform performance, research gains, and economic value will be tested separately.
See the validation plan02 / CANDIDATE ASSETS
SigmaGate and Synapto are our current candidate assets for Complementary Duality. Each brings a distinct research hypothesis to the same framework for evaluating evidence and development requirements.
Dual sigma-1 receptor activation psychedelic therapy.
Evaluate the supporting evidence and the conditions required for a viable therapeutic approach.
Single-molecule dual neurotransmitter booster psychedelic.
Assess a single-molecule concept against biological evidence and the requirements of a future therapy.
POTENTIAL INDICATIONS TO EVALUATE
PTSD Depression Anxiety Addiction
Research concepts for platform evaluation. Efficacy, consistency, safety and dosing require validation. Each asset must justify its next experiment before advancing.
Lawful wellness operations may generate revenue and dated observations that inform research questions. The platform and its potential intellectual property remain the core development strategy. Observations do not replace controlled evidence.
03 / THE PATH TO VALIDATION
An 18-month proposed roadmap moves from a defined research framework to measured comparisons and a candidate program assessment. Each stage is contingent on resources and results.
FOUNDATION & PILOT DESIGN
Define the shared research schema, first evaluation rubric, and prototype. Develop three pilot cases spanning outcome variability, a safety constraint, and a possible second indication.
Next gate A usable framework and prespecified comparisons for an initial technical pilot.
HELD-OUT COMPARISONS
Compare decisions at matched budgets against the same model with retrieval and tools, generic critique, and forward-only reasoning. Pilot committee review with and without the decision packet.
Next gate Measured decision quality, constraint handling, harmful false stops, and total cost.
CANDIDATE PROGRAM ASSESSMENT
Evaluate one program selected from SigmaGate and Synapto, based on evidence and resources, from its biological rationale through development requirements. Define a discriminating experiment and assemble a justified research or grant package for a path that meets the criteria.
Next gate An auditable assessment and a bounded, evidence-supported research plan.
REUSE & FURTHER EVALUATION
Grow private evaluation sets and test reuse across additional mechanisms or indications. Qualified experimental results update research records; any future evaluator learning is assessed separately on held-out campaigns.
Next gate Evidence of repeatable decision value and a clear basis for the next financing discussion.
8–16 weeksProposed technical pilot
24–30 tasksExploratory benchmark
The question we intend to test:
Can paired checks improve research decisions at matched budgets?
04 / LEADERSHIP
Founded at the intersection of drug discovery and intentional care, with a shared commitment to improving mental health.
Founder & Chief Executive Officer
More than 25 years in medicinal chemistry and drug discovery. Co-developed NUZYRA® and SEYSARA® and received the 2019 ACS Heroes of Chemistry recognition. Leads the platform thesis, target and mechanism strategy, and combination design.
Connect on LinkedIn (opens in a new tab)Co-founder & Chief Operating Officer
Brings more than a decade of hospitality experience and a focus on supportive environments, operational excellence, and human connection. Leads wellness operations and the collection of observations that may inform research review.
Connect on LinkedIn (opens in a new tab)THE NEXT EXPERTISE WE PLAN TO ADD
Clinical & psychiatry leadership · AI drug discovery · Pharmacology & biology · Evaluation & statistics
05 / PARTNER IN WHAT COMES NEXT
We are seeking seed partners to build and evaluate the decision platform, assess a first candidate program from SigmaGate and Synapto, and establish the team and research infrastructure to advance.
Non-confidential overview · October 2026 · PDF
PROPOSED USE OF SEED CAPITAL
Research schema, evaluation, and decision-packet tooling.
Preclinical and protocol work, contingent on evaluation.
Outcomes records and lawful supporting operations.
Specialist expertise, filings, and grant development.
POTENTIAL LONG-TERM COMMERCIAL PATHS
Research partnerships ↗ Co-development ↗ Licensed protocol packages
A CLOSER LOOK
Complementary Duality is a proposed platform with a defined research framework and validation roadmap. The seed plan supports prototype development, technical comparisons, and a first candidate program assessment. Platform performance and therapeutic or economic benefits remain to be demonstrated.
Its proposed role is research and development planning. It connects evidence about targets, mechanisms, and assets with the requirements of a future therapy, then identifies the next decision-relevant experiment. Molecule design tools could contribute inputs to that process.
SigmaGate is a proposed dual sigma-1 receptor activation psychedelic therapy. Synapto is a proposed single-molecule dual neurotransmitter booster psychedelic. Both are research concepts for platform evaluation, with efficacy, consistency, safety and dosing requiring validation.
Complementary Duality provides the shared framework for evaluating SigmaGate and Synapto. It connects each asset’s biological rationale with clinical and development requirements, records uncertainties, and identifies the next informative experiment. The broader strategy can extend to additional mechanisms, combinations and indications as evidence supports them.
The non-confidential investor deck is available above. Contact Mark Grier to discuss the research roadmap, partnership fit, or a more detailed scientific briefing.